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The interplay between mitochondrial energetics, lipid balance, and muscle insulin sensitivity has remained
a topic of intense interest and debate for decades. One popular view suggests that increased oxidative
capacity benefits metabolic wellness, based on the premise that it is healthier to burn fat than glucose.
Attempts to test this hypothesis using genetically modified mouse models have produced contradictory
results and instead link muscle insulin resistance to excessive fat oxidation, acylcarnitine production, and
increased mitochondrial H2O2-emitting potential. Here, we consider emerging evidence that insulin action
in muscle is driven principally by mitochondrial load and redox signaling rather than oxidative capacity.Introduction
Since the early discovery that type 2 diabetes is a disease inti-
mately connected to whole-body lipid imbalance, scientists in
this field have been both fascinated and frustrated by studies
aimed at understanding the interplay between glucose and fatty
acid metabolism. A fundamentally important question still
heavily debated is whether or not a shift in substrate preference
toward fat oxidation lowers disease risk. There is no disputing
that lipid oxidation confers a metabolic advantage during starva-
tion and exercise, but the role of fuel selection per se in defend-
ing against metabolic disease remains elusive. This Perspective
highlights emerging controversies surrounding the roles of mito-
chondrial function and fat oxidation in regulating insulin action
and questions the popular paradigm that it is healthier to burn
fat than glucose. Instead, the etiology of metabolic disease is
considered from the perspective of metabolic balance and mito-
chondrial bioenergetics.
Metabolic Feedback: Substrate Competition versus
Lipotoxicity
The idea that substrates compete with one another to support
respiration likely dates back to the first calorimetry studies con-
ducted in the early twentieth century (Benedict and Joslin, 1910).
It was not until the early 1960s, however, that inhibition of
glucose oxidation by fatty acids (and ketone bodies) was exper-
imentally demonstrated in perfused hearts and diaphragm
(Garland et al., 1962; Newsholme et al., 1962). In a subsequent
set of now classic studies, Randle and colleagues proposed
the concept of the glucose-fatty acid cycle (Randle et al.,
1963). The model was developed based on the finding that
increasing the supply and oxidation of fatty acids leads to cellular
accumulation of acetyl-CoA, NADH, and ATP, which allosteri-
cally inhibit pyruvate dehydrogenase (PDH), the mitochondrial
enzyme complex that couples glycolysis to glucose oxidation.
This same set of allosteric effectors activates a family of pyruvate
dehydrogenase kinases that phosphorylate PDH, further inhibit-ing the catalytic activity of the enzyme (Sugden and Holness,
2006). Randle further proposed that a rise in cellular citrate would
inhibit phosphofructokinase-1 (Denton and Randle, 1966), and
that lowering of glycolysis and pyruvate oxidation would result
in accumulation of glucose-6-phosphate, leading to allosteric
inhibition of hexokinase and thus diminished glucose uptake.
In recent years the glucose-fatty acid substrate competition
model of diabetes has been overshadowed by emphasis on
alternative mechanisms that involve ectopic accumulation of
triacylglycerol and other lipid molecules in liver and muscle.
The spotlight on this area of investigation intensified when
Shulman and coworkers challenged the idea that insulin resis-
tance stems from fatty acid-induced inhibition of hexokinase II.
Using stable isotopes and NMR methodology, these studies
pointed to glucose uptake rather than glucose phosphorylation
as the rate-limiting barrier for muscle glucose disposal in type
2 diabetic subjects (Shulman, 2000). Subsequent studies identi-
fied intramyocellular lipid content as a strong predictor of insulin
resistance. Together, these observations led to the conclusion
that lipid-induced insulin resistance is not due to inhibition of
glycolysis and glucose oxidation, but instead stems from
a more direct and proximal mechanism wherein tissue accumu-
lation of lipid signaling molecules such as diacylglycerol and
ceramide disrupt insulin-stimulated translocation of the GLUT4
glucose transporter. Support for this model grew from numerous
reports showing that intramuscular and/or hepatic content of
triacylglycerol, diacylglycerol, and/or ceramide correlate nega-
tively with insulin sensitivity (Erion and Shulman, 2010; Good-
paster and Kelley, 2002; Holland and Summers, 2008). This
relationship is evident in obese and diabetic humans as well as
in several rodent and cell culture models of metabolic disease
and/or chronic lipid exposure (An et al., 2004; Hulver et al.,
2003; Nagle et al., 2009). Taken together, these observations
have fostered widespread support for the idea that ectopic lipid
accumulation (i.e., ‘‘lipotoxicity’’) in muscle and liver is the prin-
cipal contributor to obesity-associated insulin resistance.Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 595
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of Insulin Resistance?
With evidence mounting in support of a role for ectopic fat accu-
mulation as a primary cause of insulin resistance, attention
turned to identifying potential mechanisms that underlie lipid
imbalance within the muscle. Human studies that measured
whole-body substrate selection by indirect calorimetry, fatty
acid flux across the leg, fatty acid oxidation in isolated skeletal
muscle strips, and/or maximal activities of various oxidative
enzymes in biopsy specimens strongly suggested that skeletal
muscle capacity to oxidize fat is lower in obese compared to
lean subjects, with the apparent mitochondrial insufficiencies
being most pronounced in the severely obese and/or diabetic
conditions (Hulver et al., 2003; Kelley et al., 2002; Kim et al.,
2000; Noland et al., 2003; Simoneau et al., 1995, 1999; Simo-
neau and Kelley, 1997). A notable caveat of these and several
similar animal studies is that the methods used did not account
for potential label dilution effects due to hydrolysis and catabo-
lism of endogenously derived lipids, which are more abundant
in the obese state (Boyle et al., 2011; Thyfault et al., 2010). None-
theless, investigators found that insulin sensitivity correlated
positively with skeletal muscle oxidative potential, assessed by
enzyme activities as well as genome-wide expression arrays
(Patti et al., 2003). Additional investigations employing noninva-
sive magnetic resonance spectroscopy (MRS) found that both
mitochondrial substrate flux and/or ATP synthesis rates were
depressed in muscle of elderly individuals with insulin resistance
(Petersen et al., 2003) and in lean, insulin-resistant young
subjects with a family history of type 2 diabetes (Petersen
et al., 2004). These and other studies led to the proposal that
insulin-resistant humans have faulty muscle mitochondria and
intrinsic deficiencies in oxidative metabolism that impinge on
insulin signaling by diverting fatty acids away from oxidation
and toward production of diacylglycerols and other toxic lipid
species (Lowell and Shulman, 2005; Roden, 2005).
Several lines of evidence, however, do not support the idea
that mitochondrial dysfunction is a root cause of lipotoxicity
and insulin resistance. First, conceptually, this hypothesis is
incompatible with the principles of bioenergetics. Mitochondrial
respiration in all cells is governed by energy demand, i.e., the
energy utilized to support the basal or ‘‘idling’’ activity of the
respiratory system plus that required for ATP regeneration.
Lower rates of substrate flux and/or ATP synthesis measured
at rest should not be interpreted as evidence of mitochondrial
dysfunction nor blamed for local accumulation of lipid metabo-
lites. In general, even obese and/or diabetic individuals have
enoughmitochondrial reserve to substantially increase substrate
flux and ATP synthesis to meet the energy demands of light to
moderate contractile activity. Similarly, individual differences in
muscle mitochondrial content and the specific activities of
b-oxidation enzymes should have little bearing on intramuscular
lipid accumulation, because oxidative phosphorylation is rarely
operating at maximal capacity. Thus, regardless of mitochon-
drial oxidative capacity, intracellular lipids amass whenever the
supply of fatty acids exceeds the energy needs of the cell. In
other words, supply must adjust to demand, not vice versa.
Second, high-fat feeding in rodents actually increases rather
than decreases muscle capacity to catabolize lipids due to upre-
gulation of several key mitochondrial and peroxisomal enzymes596 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.(Hancock et al., 2008; Koves et al., 2005; Muoio et al., 2012;
Noland et al., 2007; Turner et al., 2007). Despite adaptations
that favor fat catabolism, ectopic lipids still accumulate because
supply outpaces demand. It is only after several months on
a high-fat diet that mitochondrial oxidative capacity declines
(Bonnard et al., 2008). Lastly, direct and rather compelling exper-
imental evidence arguing against the mitochondrial dysfunction
theory comes from several distinct transgenic mouse models
with targeted disruptions in specific mitochondrial proteins or
master transcriptional regulators of mitochondrial biogenesis.
As anticipated, these mice have severely compromised oxida-
tive performance, but contrary to the predicted development
of insulin resistance, many of these transgenic models display
increased insulin sensitivity relative to wild-type mice, even
when challenged with a fat-enriched diet (reviewed in Muoio,
2010).
The potential impact of changes in skeletal muscle mitochon-
drial content, however, should not be lost in the cause or conse-
quence debate. Electron microscopy images of skeletal muscle
from mice on a prolonged high-fat diet reveal profound changes
in the appearance of mitochondria, including visible swelling and
disarrayed cristae (Bonnard et al., 2008). Skeletal muscle from
obese humans with or without diabetes is characterized by
reduced overall mitochondrial content with evidence of morpho-
logical changes similar to those in the animal models (Chomen-
towski et al., 2011; Kelley et al., 2002; Ritov et al., 2005). These
findings suggest that at some point in the etiology of diet-
induced obesity/diabetes, mitochondrial architecture begins to
deteriorate, ultimately leading to mitophagy and the complete
dissolution of the organelle (Mitsuhashi et al., 2011). This loss
of mitochondrial integrity is likely to compromise exercise
tolerance. Moreover, because an estimated 10%–25%of resting
metabolic rate is attributed to respiration that supports mito-
chondrial proton leak (i.e., ‘‘idling’’) (Rolfe and Brown, 1997),
and because skeletal muscle represents a high percentage of
body mass, a decline in mitochondrial density in skeletal muscle
due to disease or aging could decrease overall basal metabolic
rate and thus energy requirements (Brand, 1990). Without a
corresponding reduction in caloric intake, the probability that
fuel supply will exceed demand increases, not because of dimin-
ished oxidative capacity but because the costs of maintaining
energy balance decrease.
Metabolic Imbalance: Flooding the Mitochondria
What does happen to muscle mitochondria during the initial
phases of overnutrition and insulin resistance? Emerging
evidence suggests that the carbon load on the muscle’s oxida-
tive machinery begins to mount, such that the rate of fatty acid
catabolism persistently surpasses the drive for ATP resynthesis.
This situation first came to light with the discovery that both
diet-induced and genetic forms of insulin resistance were asso-
ciated with high rates of incomplete fat oxidation, evidenced by
intramuscular accumulation of several mitochondrial-derived
fatty acylcarnitine intermediates and reduced levels of TCA cycle
intermediates (Koves et al., 2005, 2008). The acylcarnitines are
produced by a family of acyltransferase enzymes that reside
principally in the mitochondria and convert acyl-CoA molecules
to their cognate carnitine esters. Thesemetabolites are generally
viewed as byproducts of mitochondrial metabolism that report
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specific catabolic enzymes. Interpretation of the foregoing
metabolite profiles was informed by experiments in which fuel
metabolism, mitochondrial function, and respiratory capacity
were assessed by several complementary methods, including
whole-body indirect calorimetry, in vitro flux analysis using radio-
labeled tracers, and polarographic measurement of respiration.
In aggregate, the results showed that the early stages of diet-
induced insulin resistance are characterized by increasing
b-oxidation and no change in respiratory capacity (Hancock
et al., 2008; Kraegen et al., 2008; Noland et al., 2009). Similar
abnormalities in acylcarnitine accumulation and incomplete
b-oxidation have been identified in humans with obesity or
type 2 diabetes (Adams et al., 2009; Huffman et al., 2009; Mihalik
et al., 2010) and in primary human skeletal myocytes derived
from obese compared to lean subjects (Bell et al., 2010; Kovalik
et al., 2011). In the ensuing discussion, we consider the biolog-
ical relevance of these observations viewed against a backdrop
of recent reports that have reshaped our current understanding
of mitochondrial bioenergetics and insulin action.
Fueling the Furnace: Accelerating versus Overloading
b-Oxidation
Widespread speculation that a ‘‘defect’’ in mitochondrial fatty
acid oxidation is a major factor in the etiology of diet-induced
insulin resistance raised the prospect that any intervention
that promotes fatty acid oxidation should relieve the toxicity
caused by accumulated lipid metabolites. This logic formed
the basis of numerous studies that used genetic or pharmaceu-
tical approaches to investigate the consequences of enhanced
b-oxidation, the outcomes of which are seemingly conflicted.
However, in many instances, the importance of accounting for
all energy balance parameters was overlooked, which in turn
compromised the original interpretation of the work and contrib-
uted to growing confusion in the literature. A careful reconsider-
ation of some of these studies in the context of bioenergetics
offers some surprising clarity.
An enlightening example that speaks to this discussion is the
recent controversy over the utility of acetyl-CoA carboxylase 2
(ACC2) as a potential antiobesity drug target. ACC2 appears to
be localized on the outer mitochondrial membrane (Abu-Elheiga
et al., 2001) where it catalyzes the synthesis of malonyl-CoA,
a potent inhibitor of carnitine palmitoyltransferase-1 (CPT-1),
the enzyme that functions as the gatekeeper for fatty acid entry
into the mitochondria. Absence of ACC2 activity would thus be
predicted to limit formation of malonyl-CoA and favor fatty acid
oxidation. Indeed, Acc2/ mice proved to have higher whole-
body and muscle fatty acid oxidation rates (Abu-Elheiga et al.,
2001, 2003). These animals were also hyperphagic but main-
tained normal body weight, glycemic control, and muscle insulin
sensitivity, even when fed a high-fat diet (Abu-Elheiga et al.,
2003; Choi et al., 2007). Both fat and carbohydrate oxidation
were simultaneously increased in Acc2/ mice, which was
curiously credited as the impetus for increased total body energy
expenditure without consideration of potential changes in
energy demand (Choi et al., 2007). Nevertheless, based on the
reduced fat mass and improved glucose metabolism evident in
these mice, ACC2 became a prime target for pharmaceutical
development (Keil et al., 2010). Intriguingly, however, two othergroups have recently generated whole-body- and muscle-
specific Acc2 knockout models and found no effect of the
gene deletion on body weight, food intake, body composition,
and susceptibility to diet-induced obesity and glucose intoler-
ance (Hoehn et al., 2010; Olson et al., 2010). Instead, the
genetically engineered switch to fat catabolism was offset by
diminished glucose oxidation and a reciprocal rise in de novo
lipogenesis. In these second generation models, total energy
expenditure was either unaffected (Hoehn et al., 2010) or only
slightly increased (Olson et al., 2010). Taken together, these find-
ings suggest that simply shifting substrate selection in favor of
fat oxidation does not protect against diet-induced insulin resis-
tance when whole-body energy balance is unchanged.
CPT-1 itself has been a favorite target of studies aimed at
elucidating the relationship between fat oxidation and insulin
action; however, this approach has produced mixed interpreta-
tions. In type 2 diabetic humans and in obese rodents, oral
administration of CPT-1 inhibitors such as etomoxir and oxfeni-
cine consistently elevates glucose oxidation and ameliorates
hyperglycemia and hyperinsulinemia (Barnett et al., 1992;
Deems et al., 1998; Dobbins et al., 2001; Fragasso et al., 2009;
Hu¨binger et al., 1997). However, when insulin sensitivity was
assessed by the euglycemic clamp technique, some studies
reported improvements after etomoxir treatment whereas others
found the opposite effect (Dobbins et al., 2001; Hu¨binger et al.,
1997). Interpretation of these studies is further complicated by
the observation that chronic administration of etoxomir causes
severe hepatic steatosis while also provoking a state of height-
ened oxidative stress (Vickers et al., 2006). Thus, potent inhibi-
tion of liver CPT-1 clearly leads to undesirable outcomes,
whereas the potential utility of specifically inhibiting skeletal
muscle CPT-1 remains unclear. Conversely, overexpression of
CPT-1 in cultured myocytes or rat skeletal muscles using re-
combinant adenovirus or electroporation techniques has been
shown to enhance insulin-stimulated glucose uptake (Bruce
et al., 2009; Henique et al., 2010; Perdomo et al., 2004; Sebas-
tia´n et al., 2007). In these studies investigators attributed
improvements in insulin action to relatively modest increases in
fat oxidation, assessed by CO2 production assays. Notably,
however, the genetic approaches used in these studies yield
notoriously poor transfection efficiencies, thereby raising the
question of whether enhanced insulin action measured in the
entire population of myocytes/myofibers was actually due to
events occurring within the transfected cells. It is possible that
a minority population of myocytes harboring massive overex-
pression of CPT-1 protected neighboring cells by acting as
a sink for surplus fatty acids, due not only to small increases in
complete fat oxidation but also by virtue of their robust capacity
to produce and export long-chain acylcarnitines (Noland et al.,
2009). Moreover, massive overexpression of any mitochondrial
membrane protein tends to disrupt the native stoichiometry
and integrity of the mitochondrial membrane, generating an arti-
factual acceleration in proton conductance and a concomitant
increase in energy expenditure (Cadenas et al., 2002; Harper
et al., 2002; Henique et al., 2010; Perdomo et al., 2004; Sebas-
tia´n et al., 2007),
Another approach that is commonly deployed to evaluate
the role of mitochondrial fatty acid oxidation in the etiology of
insulin resistance centers on exploitation of the peroxisomeCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 597
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a family of lipid-activated nuclear receptors that stimulate
expression of genes involved in transport and oxidation of fatty
acids (Desvergne et al., 1998). Administration of synthetic
agonists of PPARa and PPARb/d have been shown to ameliorate
lipid-induced insulin resistance in C2C12 cells and obese
rodents (Coll et al., 2010; Guerre-Millo et al., 2000; Kra¨mer
et al., 2005; Tanaka et al., 2003). Based on these findings,
muscle-specific transgenic overexpression of PPARa or PPARg
coactivator-1a (PGC-1a), a promiscuous nuclear receptor coac-
tivator that promotes mitochondrial biogenesis, was expected to
defend against metabolic disease. However, despite impressive
upregulation of several oxidative enzymes and markedly
enhanced capacity for fat oxidation in muscle, both of these
transgenic mouse models were more susceptible to diet-
induced insulin resistance (Choi et al., 2008; Finck et al., 2005).
Why do pharmacological and genetic activation of the same
gene induce opposite responses? The answer probably relates
to cellular bioenergetics. In cultured L6myotubes, the repressive
effects of PPARa overexpression on glucose uptake are
reversed by addition of dinitrophenol (Finck et al., 2005), a proto-
nophore that elevates energy demand by increasing proton
conductance of the mitochondrial inner membrane. This implies
that PPARa overexpression creates a situation wherein forced
flux through b-oxidation outpaces the demand of the respiratory
system and that the added reducing pressure imposed by high
rates of incomplete oxidation interferes with insulin action. This
possibility is underscored by the finding that relief was gained
simply by increasing energy demand. But why then do synthetic
agonists of the PPARs appear to improve rather than impair
insulin sensitivity? Here again, changes in the rates of b-oxida-
tion must be considered in the context of energy demand. Treat-
ing mice with PPARa or PPARb/d agonists also induces, either
directly or indirectly, an increase in whole-body oxygen
consumption without affecting caloric intake, thus accounting
for lower rates of weight gain in response to high-fat feeding
(Guerre-Millo et al., 2000; Tanaka et al., 2003). Whereas treat-
ments with PPAR agonists do indeed encourage a shift in meta-
bolic currency toward fat oxidation, the drug-induced rise in total
body energy expenditure is likely to underlie the absolute
increase in flux through b-oxidation, thereby mitigating the
‘‘mitochondrial stress’’ normally associated with overnutrition.
Fuel Selection and Metabolic Flexibility: Timing Is
Everything
The concept of metabolic flexibility emphasizes the importance
of choosing the right fuel at the right time. In recent years it has
become increasingly apparent that nutrient-induced substrate
switching is often compromised in the settings of obesity and
type 2 diabetes (Kelley and Mandarino, 2000). This phenom-
enon, commonly known as ‘‘metabolic inflexibility,’’ was first
introduced in a report showing that healthy individuals shift
from robust fat oxidation in the fasted state to a high rate of
glucose oxidation in response to a hyperinsulinemic-euglycemic
clamp (measured by whole-body or leg RQ), whereas obese and
type 2 diabetic subjects showed little response (Kelley et al.,
1999). Similar findings emerged from several subsequent studies
in both humans and rodents (Koves et al., 2008; van Herpen
et al., 2011). The molecular basis and pathophysiological rele-598 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.vance of metabolic inflexibility remain uncertain. One viewpoint
suggests that the inability to appropriately activate glucose
oxidation in response to a meal simply reflects a secondary
consequence of impaired insulin action (Galgani et al., 2008).
Evidence for a more complex scenario comes from the finding
that obesity-induced perturbations in substrate switching are
evident in isolated mitochondria (Koves et al., 2008; Noland
et al., 2009), suggesting that defects in mitochondrial fuel selec-
tion are at least partly independent of insulin signaling and could
contribute to impaired glucose disposal at the systemic level.
Themetabolic inflexibility paradigm leads back to the question
of whether chronic oversupply of lipid fuel results in persistent
suppression of PDH activity, as originally proposed by Randle.
Muscle accumulation of acylcarnitines and pyruvate observed
in insulin-resistant states (Boyle et al., 2011; Thyfault et al.,
2010) is consistent with an increase in mitochondrial acyl CoA
levels that impose negative feedback on PDH. The notion that
pyruvate trafficking can indeed impact systemic glucose homeo-
stasis is strengthened by studies in mice lacking PDH kinase 4,
which have elevated PDH activity and enhanced glucose toler-
ance (Jeoung and Harris, 2008). Moreover, recent evidence
suggests that lowering of mitochondrial acyl CoAs, resulting
in increased PDH activity and improved metabolic flexibility,
can be achieved via dietary supplementation with L-carnitine
(Noland et al., 2009; Power et al., 2007). In these studies,
improvements inmetabolic function at thewhole-body andmito-
chondrial level corresponded with robust increases in plasma
and urinary concentrations of acetylcarnitine (Noland et al.,
2009), a metabolite that is produced from acetyl CoA and carni-
tine by the mitochondrial matrix enzyme carnitine acetyltransfer-
ase (CrAT). Unlike their acyl-CoA precursors, acylcarnitines can
traverse cellular membranes. Accordingly, interconversion of
these molecules is thought to play a key role in regulating
mitochondrial acyl-CoA balance. Ensuing studies in mice with
conditional deletion of Crat confirmed an essential role for this
enzyme in defending whole-body glucose homeostasis (Muoio
et al., 2012). Thus, muscle-specific ablation of Crat resulted in
systemic glucose intolerance, complete loss of carnitine-stimu-
lated PDH activity, and blunted switching from fatty acid to
glucose substrate at the whole-body level and in isolated mito-
chondria. These results suggest that CrAT opposes the Randle
cycle by permitting mitochondrial efflux of excess carbons,
which thereby facilitates an efficient transition from fat to glucose
during the fasted-to-fed transition.
Mitochondrial Stress: A Contemporary View of the
Randle Cycle
The acylcarnitine signature of insulin-resistant states raises
speculation that muscle insulin sensitivity is governed by mito-
chondrial load, rather than oxidative potential. Thus, distur-
bances in substrate selection, anaplerotic and cataplerotic
carbon flux, production of reactive oxygen species (ROS), and
intracellular redox balance might report on local energetic tone
as a means to coordinate insulin sensitivity with cellular demand
for glucose substrate. If true, how might lipid-overloaded mito-
chondria antagonize insulin action? Although decades of
research have firmly established a reciprocal relationship
between glucose and fat oxidation, the role of b-oxidation per
se as an underlying cause of obesity-associated glucose
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whether or not persistent suppression of PDH and PFK-1 leads
to accumulation of glucose-6-phosphate and inhibition of
hexokinase II. Whereas the aforementioned NMR-based studies
in diabetic humans disputed this mechanism (Shulman, 2000),
experiments employing a counter-transport technique con-
cluded that limitations to muscle glucose uptake in rodents fed
a high-fat diet reside at the levels of glucose delivery and phos-
phorylation, as well as GLUT4 transport (Wasserman, 2009).
These results fit a model of distributed flux control wherein the
barrier to muscle glucose uptake shifts from the transport step
to phosphorylation and metabolism once the GLUT4 trans-
porters are mobilized by insulin or exercise (Wasserman,
2009). Accordingly, feedback inhibition of PDH and hexokinase
might serve as themajor mode of glucose disuse during the early
phases of weight gain and hyperinsulinemia, prior to the onset of
overt defects in insulin signaling.
Compartmentalization of glycolytic intermediates might also
factor into the foregoing discrepancies. For example, hexoki-
nases I and II can translocate to the mitochondrial outer
membrane where their catalytic activities are less sensitive to
product inhibition (Azoulay-Zohar et al., 2004; Hashimoto and
Wilson, 2002; John et al., 2011). Although the functional rele-
vance of mitochondrial-associated hexokinase activity is
unknown, a potential role in regulating glucose uptake is sug-
gested by its intriguing connection to thioredoxin-interacting
protein (TXNIP), a redox-regulatory protein belonging to the a-ar-
restin family (Chutkow et al., 2010; Hui et al., 2008). TXNIP not
only binds to and inhibits thioredoxin, but also antagonizes
glucose uptake through a yet undefined mechanism (Parikh
et al., 2007). In skeletal muscle, TXNIP gene expression is
controlled by MondoA, a member of the bHLHZip family of
transcription factors that dimerizes with another member of
this family, MLX, to gain nuclear entry and DNA binding capacity.
Interestingly, MondoA:MLX complexes are latently held at the
outer mitochondrial membrane and translocate to the nucleus
when glycolytic intermediates accumulate (Sloan and Ayer,
2010), an event that requires hexokinase activity (Stoltzman
et al., 2008). TXNIP abundance is elevated in muscles of diabetic
rodents and humans, suggesting that glycolytic intermediates
are likewise increased under insulin-resistant conditions. Taken
together, these provocative new findings imply that colocaliza-
tion of MondoA and hexokinase at the mitochondrial membrane
reflects a mechanism that couples mitochondrial sensing of
glycolytic flux to cellular glucose transport. Thus, competition
between oxidative substrates might increase a mitochondrial-
localized pool of glucose-6-phosphate that in turn triggers Mon-
doA translocation and transcriptional induction of TXNIP to
reduce uptake of unwanted glucose fuel (Figure 1).
Are there metabolic signals beyond glucose-6-phosphate
that permit crosstalk between mitochondria and glucose trans-
port? The acylcarnitines themselves are seemingly attractive
candidates; however, the weight of evidence at this stage
suggests that these metabolites function in a homeostatic
capacity to relieve mitochondrial stress (Figure 1) (Muoio et al.,
2012; Mingorance et al., 2011; Noland et al., 2009; Power
et al., 2007). Another hypothesis that has gained momentum in
recent years centers on the premise that mitochondrial-derived
ROS modulate insulin signaling (Bloch-Damti and Bashan,2005; Evans et al., 2005). This mechanism is attractive in that
it could explain insulin resistance caused by overconsumption
of sugar and protein, as well as fat. Thus, chronic elevations in
incomplete oxidation of fatty acids and branched-chain amino
acids (Newgard, 2012) might foster a mitochondrial microenvi-
ronment that is conducive to ROS production. The initial
steps in oxidation of fatty acids and amino acids (mediated by
long-chain acyl-CoA dehydrogenase [LCAD] and branched-
chain ketoacid dehydrogenase [BKAD], respectively) generate
FADH2, which donates electrons directly to the ubiquinone (Q)
cycle via the electron transfer flavo protein (ETF). Two other
FAD-linked complexes that feed into the Q cycle include
complex II (succinate dehydrogenase), the entry point for amino
acid-derived succinyl CoA, and the mitochondrial isoform of
glycerol-3-phophate dehydrogenase, which shuttles electrons
from cytosolically localized glycolytic intermediates to the mito-
chondrial respiratory chain. Because these electrons bypass
complex I, heightened flux through the foregoing enzyme
complexes, in the absence of high ATP demand (i.e., exercise),
is predicted to elevate reducing pressure within the system,
particularly the backpressure on complex I, thereby increasing
ROS production (see Fisher-Wellman and Neufer, 2012 for
review) (Figure 1). This sets the stage for a highly plausible
scenario wherein chronic overabundance of these nutrients
leads to persistent pressure on the ETC and resultant disruption
of redox balance and ROS signaling.
ROS are now viewed as bona fide signaling molecules, and
oxidant stress is known to activate several of the serine kinases
and transcription factors that have been linked to insulin resis-
tance, including c-jun amino-terminal kinases (JNK), IkB kinase
catalytic subunit b (IKK-b), NF-kappaB transcription factor
(NF-kB), and protein kinase C (PKC) (Bloch-Damti and Bashan,
2005; Chakraborti and Chakraborti, 1998). Treatment of geneti-
cally obese/diabetic rodents with antioxidant nutrients has
been shown to improve insulin action and glucose homeostasis
(Henriksen, 2006; Hoehn et al., 2009; Houstis et al., 2006). A
subsequent report provided compelling evidence linking insulin
resistance to mitochondrial H2O2 emission (Anderson et al.,
2009). In these studies, insulin-resistant states were associated
with increased H2O2 emission from muscle mitochondria and
decreased tissue levels of reduced relative to oxidized gluta-
thione (GSH:GSSG), a well-established biomarker of oxidative/
reductive stress. Moreover, genetic or pharmacological manipu-
lations that lowered mitochondrial ROS production preserved
insulin action in lipid-treated myotubes (Hoehn et al., 2009) and
in mice fed a high-fat diet (Anderson et al., 2009; Hoehn et al.,
2009; Lee et al., 2010). ROS signaling and redox sensing rely
heavily on the interdependent glutathione and thioredoxin
reducing systems. Both use the reducing power of NADPH to
mitigate oxidative stress and to modulate reversible oxidation/
reduction of protein thiols/disulfides. These so-called ‘‘sulfur
switches’’ are gaining increasing recognition for their regulatory
roles in cell signaling and metabolic control (Hui et al., 2008;
Jones, 2008) and have recently been suggested to form an intra-
cellular redox circuit linking mitochondrial H2O2 emission to the
control of redox-sensitive phosphatases that target the insulin
signaling pathway (see Fisher-Wellman and Neufer, 2012 for
review). This intriguing collection of findings calls for further
investigation of ROS signaling and redox imbalance as anCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 599
Figure 1. Working Model of Nutrient-Induced Mitochondrial Stress
Fatty acids, branched-chain amino acids (BCAA), and glucose are degraded to acetyl-CoA, which serves as the universal substrate for the tricarboxylic acid
cycle. Oversupply of these nutrients results in incomplete substrate catabolism and mitochondrial accumulation of acyl-CoA intermediates that are readily
converted to their membrane permeant acylcarnitine counterparts. When substrate catabolism exceeds ATP demand, the high energy charge of the cell
discourages glucose uptake by inhibiting hexokinase (HK), phosphofructokinase (PFK), and pyruvate dehydrogenase (PDH) and by activating thioredoxin-in-
teracting protein (TXNIP). Heightened reducing pressure (FADH2 and NADH) on the Q cycle of the electron transport chain promotes ROS generation ($O2 and
H2O2) in excess of antioxidant capacity (e.g., superoxide dismutase [SOD], peroxiredoxin [PRx], and glutathione peroxidase [GPx]), therebymodulatingmetabolic
enzymes and redox-sensitive signaling proteins that control fuel selection, glucose trafficking, and insulin action. BKAD, branched chain ketoacid dehydro-
genase; BHAD, b-hydroxyacyl-CoA dehydrogenase; CrAT, carnitine acetyltransferase; DHAP, dihydroxyacetone phosphate; ETF, electron transfer favoprotein;
G3PDH, cytosolic(c)/mitochondrial(m) glycerol-3-phosphate dehydrogenase; LCAD, long-chain acyl-CoA dehydrogenase; SCHAD, short-chain hydroxyacyl-
CoA dehydrogenase. See text for further detail.
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insulin action.
Also relevant to the topic of mitochondrial stress are recent
studies linking fuel metabolism and overnutrition to changes in
the acylation state of mitochondrial proteins (Hirschey et al.,
2009; Huang et al., 2010). Remarkably, application of mass
spectrometry-based proteomics has led to the estimation
that at least 20% of the mitochondrial proteome is acetylated.
Moreover, every major pathway of intermediary metabolism
was represented among the list of acetylated proteins. Subse-
quent studies identified three members of the sirtuin family of
deacetylases, sirt3, sirt4, and sirt5, which localize to the mito-
chondria. Sirt3 is an established deacetylase whose targets
include long-chain acyl-CoA dehydrogenase (LCAD), succinate
dehydrogenase, and Mn superoxide dismutase (SOD2) (Hir-
schey et al., 2010; Qiu et al., 2010). Interestingly, muscles of
Sirt3 knockout mice have increased acetylation of LCAD,600 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.SOD2, and several ETC complexes, which is accompanied by
elevated acylcarnitines, TBARS, and pJNK (Jing et al., 2011;
Qiu et al., 2010). These animals also develop multiple elements
of the metabolic syndrome with aging (Hirschey et al., 2011).
Moreover, recent studies have revealed novel roles for sirt4
and sirt5 in regulating protein malonylation and succinylation
(Du et al., 2011; Peng et al., 2011; Zhang et al., 2011), implying
that mitochondrial accumulation of various short-chain acyl-
CoAs could trigger broad-ranging metabolic consequences via
their impact on protein modifications.
Stress Relief: A Matter of Thermodynamics
In addition to those already discussed, a remarkable number of
transgenic mouse models are resistant to high-fat diet-induced
obesity and insulin resistance (Chen and Farese, 2001; Reitman,
2002). The specific molecular targets are quite varied and too
numerous to mention explicitly, but include genes involved in
Cell Metabolism
Perspectiveglucosemetabolism (Hakimi et al., 2007), growth factor signaling
(Molero et al., 2006), inflammation (Chiang et al., 2009), mito-
chondrial function (Li et al., 2000), lipid biosynthesis (Smith
et al., 2000), lipid signaling (Mancuso et al., 2010), and transcrip-
tional metabolic regulators (Fischer et al., 2009). Despite the
diversity of these genetic targets, nearly all of these models
have elevated whole-body VO2 with similar or even greater
food intake relative to their wild-type littermates. These findings
suggest that increased energy expenditure is the common
underlying mechanism accounting for the lean, insulin-sensitive
phenotype. Elevated energy expenditure can arise only from an
increase in thermogenesis (i.e., uncoupling), heavier reliance on
inefficient ATP regenerating systems, enhanced carbon flux
through futile energetic cycles, or increased physical/locomotor
activity (Butler and Kozak, 2010). Also noteworthy, many of the
same genetic manipulations resulted in the activation of
50AMP-activated kinase (AMPK), which phosphorylates and
inactivates ACC, thereby lowering cellular malonyl CoA levels
and promoting fat oxidation. It is often presumed that antidia-
betic protection associated with or afforded by heightened
AMPK activity is due mainly to a rise in b-oxidation (Zhang
et al., 2010). Seemingly overlooked, however, is that AMPK
functions as a critical cellular sensor of energy deficit that in
turn triggers a multifaceted cascade of catabolic responses at
the levels of cell signaling, metabolism, and transcriptional
control (Kahn et al., 2005). Accordingly, its activation offers a
strong hint that the maneuvers under consideration first elicited
a negative energy balance in the affected tissues.
There are three points to draw from the preceding sections.
First, because cellular and mitochondrial bioenergetics is gov-
erned by the rate of energy expenditure, any change in the rate
of substrate oxidation must be considered in the context of
energy demand. Second, because even a small increase in
energy demand will completely relieve the reducing pressure
and ROS production in mitochondria created by a positive
energy balance, the increased energy expenditure evident in
many of the mouse models that resist diet-induced metabolic
abnormalities could represent the common underlying protec-
tive mechanism. The third point is that the flux rate through
b-oxidation relative to energy demand appears to be a particu-
larly important determinant of insulin sensitivity in skeletal
muscle. Several lines of evidence support this contention. In
the lean but severely insulin-resistant muscle-specific PPARa
transgenic mice, administration of the CPT-1 inhibitor oxfenicine
blocked fatty acid oxidation and rescued insulin sensitivity,
despite inducing profound lipid accumulation in muscle (Finck
et al., 2005). Similarly, mice that were genetically engineered to
have restricted flux through b-oxidation in muscle maintain
normal insulin sensitivity on a high-fat diet even though lipid
content of muscle, liver, and/or adipose tissue remain elevated
(Finck et al., 2005; Guerre-Millo et al., 2001; Koves et al., 2008;
Tordjman et al., 2001). Moreover, whereas wild-type animals
consuming a high-fat diet manifest a persistent mismatch in
mitochondrial lipid load relative to energy demand, resulting in
muscle accumulation of partially oxidized fatty acylcarnitine
intermediates (Koves et al., 2005, 2008), correction of this imbal-
ance by one of three disparate strategies (lowering carbon
import, increasing the rate of energy expenditure, or enhancing
rates of carbon efflux) restored both mitochondrial energeticbalance and systemic glucose tolerance (Koves et al., 2005,
2008; Noland et al., 2009). Collectively, these data support the
principle that increasing flux through b-oxidation without a corre-
sponding boost in energy demand imposes unwarranted
reducing pressure on the respiratory system, which in turn
impinges upon redox balance and insulin action. Conversely, if
flux through b-oxidation increases as a consequence of energy
demand, the system then operates in metabolic balance, and
insulin sensitivity is maintained.
Closing Remarks: Therapeutic Implications
The past two decades of diabetes research have uncovered an
intricate network of metabolic and molecular events that partici-
pate in obesity-related organ dysfunction and the subsequent
demise of systemic glucose control. Prominent among these are
perturbations in lipid signaling, inflammation, endoplasmic retic-
ulum stress, and mitochondrial stress. As revealed throughout
this series of Perspectives, the signaling pathways involved in
these responses intersect at multiple nodes and are likely to act
in a collaborative fashion to dampen whole-body insulin action.
Interestingly, one common denominator that factors into each of
the foregoing nutrient stress mechanisms is mitochondrial ROS
production, which can be positioned both upstream and down-
streamof the foregoing cellular insults. Although a unifyingmech-
anism of nutrient-induced insulin resistance seems improbable
given the pathophysiological complexities of the disorder, ROS
signalingmight serveasacritical site of convergenceandapoten-
tial avenue for nutraceutical and/or pharmaceutical intervention.
The relative contributions of various stress-sensing mecha-
nisms to the origin and progression of insulin resistance is likely
to depend on tissue specificity, diet composition, and genetic
predisposition. The current Perspective focused on the relation-
ships between lipid stress, glucose disuse, and mitochondrial
metabolism in skeletal muscle. We highlighted a new wave of
evidence in dispute of the simple prediction that lifestyle-related
insulin resistance in muscle is caused by sluggish mitochondria
with inherent deficits in fat oxidation. Instead, we suggest that
the etiology ofmuscle insulin resistance is grounded in the funda-
mental principles that govern cellular and mitochondrial bioener-
getics and the redox pressures that are placed on the respiratory
system when energy supply persistently outpaces energy
demand (Figure 2).Careful considerationof thesebasicprinciples
raises doubt about the popularized concept of ‘‘exercise in a pill.’’
Thus, mitochondrial adaptations that benefit exercise perfor-
manceare those that favor energyefficiencyandglucosesparing,
whereas therapeutic agents targeted against obesity and dia-
betesshouldpromoteenergetic inefficienciesandglucoseutiliza-
tion. This contrast implies that pharmaceuticals designed to
evoke an exercise trained phenotype (e.g., heightened fat oxida-
tion and/or mitochondrial biogenesis) without a corresponding
increase in energy expenditure might do more harm than good
when administered to inactive, glucose-intolerant patients.
At least one general consensus in this field is that the recent
surge in the prevalence of insulin resistance stems largely from
inactivity, caloric excess, and the poor nutrient quality of heavily
processed foods. Chronic exposure to these adverse metabolic
conditions imposes a persistent nutrient burden on most, if not
all, subcellular compartments, leading inevitably to cellular
distress and dysfunction at multiple levels. Where do the mostCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 601
Figure 2. Predicted Daily Fluctuations in Mitochondrial Membrane
Potential in Relation to Metabolic Balance
(A and B) Schematic illustration showing 24 hr predicted fluctuations in mito-
chondrial membrane potential for an individual out of metabolic balance due to
excess caloric intake and sedentary lifestyle (A) and an individual in metabolic
balance due to appropriate caloric intake and active lifestyle (B). Dotted line
indicates approximate threshold membrane potential at which electrons begin
to leak to from superoxide. Arrows signify calorie intake. Red indicates
progressively increasing H2O2 generation, and blue indicates progressively
increasing O2 consumption.
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Perspectiveattractive therapeutic opportunities lie? The obvious answer is
to attack the root cause of the problem, rather than the constel-
lation of molecular symptoms. The two therapies that are unde-
niably effective in combating nutrient overload include dietary
modification and habitual exercise. In practice, however, long-
term maintenance of lifestyle modifications has proven chal-
lenging, evidenced by disappointingly high recidivism rates
(Turk et al., 2009). These grim statistics call for the development
of centrally acting drugs that facilitate behavior modification
strategies and/or peripherally targeted compounds that promote
energy wasting.
Whereas drug development to thwart obesity and diabetes is
clearly necessary, this approach is neither practical nor sustain-
able as a first line of defense. Over two-thirds of U.S. adults are
overweight or obese. Thus, the long-term solution to the current
epidemic of metabolic disease must encompass substantive
efforts aimed at prevention in children and young adults. Prog-
ress toward this end will require that metabolic scientists engage
in national discussions centering on the grave need for bold
public health initiatives and environmental restructuring rather
than the promise of a magic pill.
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